Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Usefulness of Ki67 Proliferative Index to Predict Recurrence and Benefit From Adjuvant Chemotherapy in Hormone Receptor (HR)-Positive Breast Cancer

NCT01273415 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT01273415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01273415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Usefulness of Ki67 Proliferative Index to Predict Recurrence and Benefit From Adjuvant Chemotherapy in Hormone Receptor (HR)-Positive Breast Cancer
Lead sponsor
Samsung Medical Center
Phase
Observational
Overall status
Completed
Start date
August 31, 2010
Completion date
January 31, 2011
Enrollment
1,070 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer